20120131.TNBC
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.380
- G2M_CHECKPOINT+0.330
- E2F_TARGETS+0.320
- WNT_BETA_CATENIN_SIGNALING+0.240
- UV_RESPONSE_DN+0.210
- HEDGEHOG_SIGNALING+0.200
- TGF_BETA_SIGNALING+0.200
- PROTEIN_SECRETION+0.190
- MYC_TARGETS_V1+0.180
- MITOTIC_SPINDLE+0.170
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.590
- INTERFERON_GAMMA_RESPONSE-0.550
- ALLOGRAFT_REJECTION-0.470
- INFLAMMATORY_RESPONSE-0.420
- IL6_JAK_STAT3_SIGNALING-0.410
- ESTROGEN_RESPONSE_EARLY-0.390
- COMPLEMENT-0.370
- ESTROGEN_RESPONSE_LATE-0.360
- KRAS_SIGNALING_UP-0.350
- IL2_STAT5_SIGNALING-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR9879265 | — | cohortMD1 | 0.903 |
| 2 | TCGA-50-6591-01A-11R-1755-07 | — | cohortMD1 | 0.899 |
| 3 | s0122172 | — | — | 0.885 |
| 4 | 62b39052-bdb9-4ba6-9eb0-f117480c98a8 | — | — | 0.885 |
| 5 | TCGA-56-8083-01A-11R-2247-07 | — | cohortMD1 | 0.882 |
| 6 | SRR8518262 | — | E | 0.874 |
| 7 | TCGA-78-7155-01A-11R-2039-07 | — | cohortMD1 | 0.869 |
| 8 | TCGA-50-5931-01A-11R-1755-07 | — | cohortMD1 | 0.868 |
| 9 | TCGA-34-5927-01A-11R-1820-07 | — | cohortSQ1 | 0.865 |
| 10 | SRR5088887 | — | — | 0.864 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.380 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.190 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.170 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.150 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.090 | Idelalisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |